This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
L-alpha-Glycerophosphorylethanolamine is a medication indicated as an adjunct therapy in the maintenance of cognitive function in the elderly.
- Generic Name
- L-alpha-Glycerophosphorylethanolamine
- DrugBank Accession Number
- DB15872
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for L-alpha-Glycerophosphorylethanolamine (DB15872)
- Weight
- Average: 215.142
Monoisotopic: 215.055874173 - Chemical Formula
- C5H14NO6P
- Synonyms
- Ethanolamine glycerophosphate anhydrous
- L-alpha-Glycerophosphorylethanolamine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Adjunct therapy in treatment of Cognitive function abnormal •••••••••••• ••••• •••••••••• ••••••••• ••••••••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- O35QN01X8F
- CAS number
- 33049-08-0
- InChI Key
- JZNWSCPGTDBMEW-RXMQYKEDSA-N
- InChI
- InChI=1S/C5H14NO6P/c6-1-2-11-13(9,10)12-4-5(8)3-7/h5,7-8H,1-4,6H2,(H,9,10)/t5-/m1/s1
- IUPAC Name
- (2-aminoethoxy)[(2R)-2,3-dihydroxypropoxy]phosphinic acid
- SMILES
- NCCOP(O)(=O)OC[C@H](O)CO
References
- General References
- AIFA Product Information: ESTO (L-alpha-Glycerophosphorylethanolamine) tablet and solution [Link]
- External Links
- KEGG Compound
- C01233
- ChemSpider
- 392177
- ChEBI
- 143890
- ZINC
- ZINC000004095590
- PDBe Ligand
- GPE
- PDB Entries
- 1a8b / 5t1p / 6ra9
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Intramuscular; Intravenous 1000 MG Solution Oral 500 MG Tablet Oral 500 MG - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 36.5 mg/mL ALOGPS logP -2.3 ALOGPS logP -3.4 Chemaxon logS -0.77 ALOGPS pKa (Strongest Acidic) 1.87 Chemaxon pKa (Strongest Basic) 10 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 122.24 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 43.82 m3·mol-1 Chemaxon Polarizability 18.89 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0006-9600000000-1b2b9368f8875c1b0ecb Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-9210000000-c93fbdbbe4cdfa810cb4 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-9100000000-636669058f20e5d6df48 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0005-9000000000-6ea4e1f2755e5d8efaf3 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0006-9000000000-772034399070ad0810b4 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-9000000000-9eeb2f6b5e86b545c912 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 148.5468503 predictedDarkChem Lite v0.1.0 [M-H]- 126.52011 predictedDeepCCS 1.0 (2019) [M+H]+ 149.8768503 predictedDarkChem Lite v0.1.0 [M+H]+ 130.35176 predictedDeepCCS 1.0 (2019) [M+Na]+ 149.2092503 predictedDarkChem Lite v0.1.0 [M+Na]+ 139.20445 predictedDeepCCS 1.0 (2019)
Drug created at September 21, 2020 19:41 / Updated at May 10, 2021 12:36